Latest from Baylor Scott & White Cancer

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses the role of surgery in stage III non–small cell lung cancer.
Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing testing in patients with non–small cell lung cancer.
Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the role of PD-L1 in patients with squamous non–small cell lung cancer.
Ronan J. Kelly, MD, MBA, addresses the paradigm shift in stage III unresectable non–small cell lung cancer before delving into the complex field of ALK-rearranged disease.
Kartik Konduri, MD, discusses the use of combination therapies and newer agents in patients with targetable driver mutations.
Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses treatment options available for patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, on the campus of Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer.
Ghanshyam Yadav, MD, first-year resident, Baylor College of Medicine, discusses the synergy of a novel combination in the treatment of patients with HER2-overexpressing uterine serous carcinoma.
Publication Bottom Border
Border Publication
x